Pfizer's LITFULO Hits Phase 3 Goals in Vitiligo, Filing Plans Ahead
PFE is trading near its 52-week low of $23.11 (8.4% above the low).
Summary
Pfizer's LITFULO met co-primary endpoints in two Phase 3 trials for nonsegmental vitiligo, showing significant facial and total body repigmentation at Week 52. The drug, already approved for severe alopecia areata, now has a clear path to global regulatory filings for a new indication. This expands LITFULO's commercial potential into a chronic autoimmune condition with limited systemic treatment options. The safety profile was consistent with prior experience, with no new signals. The news adds to a string of positive pipeline updates from Pfizer this year, including advances in oncology and obesity. Full data will be presented at a future medical meeting, which could further define the drug's competitive positioning.
At the time of this announcement, PFE was trading at $25.04 on NYSE in the Life Sciences sector, with a market capitalization of approximately $143.3B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.